Relapsed/Refractory Multiple Myeloma: Rationale and Design of the MonumenTAL-3 Study
Following the accelerated approval of talquetamab based on MonumenTAL-1, the faculty review the need for a registrational study capable of evaluating talquetamab in earlier lines of therapy and in combination with established agents.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Multiple Myeloma Clinical Trials & Emerging Therapies
- S2209: Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM)
- Improved survival in multiple myeloma following prior detection of precursor conditions: a nationwide real-world study
- Nanomedicine-Empowered CAR‑T Therapy for Multiple Myeloma: Toward Programmable, Durable, and Precision Immunotherapy
- Reaching Consensus on Defining, Treating High‑Risk Myeloma